The DF/HCC Breast Users Committee and Resources for Research
The Breast Users Committee is the supervising body for use of the breast cancer curated clinical data and/or specimens from the DF/HCC.
The Users Committee is composed of at least one member from each participating organization which includes Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, representing the disciplines of pathology, surgery, and medical oncology, radiation oncology, and biostatistics. Members will be appointed by their respective organizations with no pre-specified term limits. The current membership of the Users Committee is presented on the FAQ page.
A wide range of clinical data and biospecimens are collected as part of several DF/HCC research protocols on our breast cancer patients treated at our institutions. These data and specimens are available to DF/HCC investigators for further research studies. The members of the DF/HCC Breast Users Committee are charged with reviewing the feasibility and scientific validity of proposed clinical and health services research and/or quality improvement projects and translational and laboratory-based projects using these DF/HCC breast data and specimen resources.
The members of the DF/HCC Breast Users Committee are charged with reviewing the feasibility and scientific validity of proposed clinical and health services research and/or qualitative improvement (QI) projects and translational and laboratory-based projects using the specimens and clinical data available through DF/HCC research protocols which govern its collection.